FULC Fulcrum Therapeutics

Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease

Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
EN
05/10/2020

Underlying

FULCFulcrum Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fulcrum Therapeutics

 PRESS RELEASE
Free
FULC Fulcrum Therape...

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Ru...

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as...

November 7, 2025 1 EN
 PRESS RELEASE
Free
FULC Fulcrum Therape...

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER tri...

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting ― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ― Live and Webcast Investor Event with Fulcrum Leadership and Medical Experts will be Hosted Onsite on Sunday, December 7 ― CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on develo...

November 3, 2025 1 EN
 PRESS RELEASE
Free
FULC Fulcrum Therape...

Fulcrum Therapeutics Announces Recent Business Highlights and Financia...

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025         ― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the PIONEER trial; on track to provide data from the 20 mg dose cohort by year-end ― ― Ended Q3 2025 with $200.6 million in cash, cash equivalents, and marketable securities; cash runway into 2028 ― CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.®...

October 29, 2025 1 EN
 PRESS RELEASE
Free
FULC Fulcrum Therape...

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conf...

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2025 financial results will be released on Wednesday, October 29, 2025, before the U.S. financial markets open. Management will host a conference ca...

October 22, 2025 1 EN
 PRESS RELEASE
Free
FULC Fulcrum Therape...

Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX...

Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 ― Preclinical data of FTX-6274 suggests potential for the treatment of castration resistant prostate cancer ― CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that it will present preclinical data for FTX-6274, an oral embryonic ...

October 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch